Brief: Ocugen Announces Ocu400 Receives Regenerative Medicine Advanced Therapy (Rmat) Designation For Treatment Of Retinitis Pigmentosa Associated With Rho Mutations
19/12/2023 12:39
Dec 19 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN ANNOUNCES OCU400 RECEIVES REGENERATIVE MEDICINE
ADVANCED
THERAPY (RMAT) DESIGNATION FOR TREATMENT OF RETINITIS PIGMENTOSA
ASSOCIATED WITH RHO MUTATIONS
* OCUGEN INC - RMAT DESIGNATION INTENDED TO HELP EXPEDITE
DEVELOPMENT OF NEW REGENERATIVE MEDICINES
* OCUGEN - WORKING WITH FDA TO FINALIZE PHASE 3 PROTOCOL
NECESSARY
TO ADVANCE DEVELOPMENT FOR OCU400 TO SUPPORT APPLICATION FOR
MARKETING AUTHORIZATION
Source text for Eikon: ID:nGNX2QmlQ7
Further company coverage: OCGN.O
((Reuters.Briefs@thomsonreuters.com;))